GlobalData on MSN6d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
Yahoo Finance6d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J ... In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with major depressive disorder (who were ...
Insider Monkey26d
Johnson & Johnson (JNJ): Among the Best Psychedelic Stocks to Buy in 2025
Johnson & Johnson (NYSE:JNJ) is advancing psychedelic medicine with Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation. Since its ...
InnovationRx: Fatal Drug Overdoses Are Falling – But Medicaid Cuts Could Halt Progress
In this week’s edition of InnovationRx, we look at the trend in fatal drug overdoses, 23andMe’s bankruptcy, the new CDC ...
Pharmaceutical Technology7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson developed the dual-acting monoclonal antibody. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its ...
pharmaphorum3d
Axsome bounces back as FDA clears depression drug
Shares in Axsome Therapeutics have rocketed on FDA approval ... to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week ...
Bausch: Potential Breakthrough in Depression Treatment to Unlock $3B Opportunity?
Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...
pharmaphorum4d
J&J’s Spravato for depression ‘should be much cheaper’
Johnson & Johnson has priced its new ... 25% and 52% cheaper to meet its value threshold. The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per ...